Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986711 | 1.00 | MAPT (0.68) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL15920894 | 0.86 | MAPT (0.65) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL15968586 | 0.85 | ALDH1A1 (0.58) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL29825107 | 0.85 | ALDH1A1 (0.58) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL29822834 | 0.82 | ALDH1A1 (0.64) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5393044 | 0.82 | ALDH1A1 (0.64) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL383936 | 0.82 | CES2 (0.59) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL14012582 | 0.82 | CES2 (0.59) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL29664708 | 0.82 | CES2 (0.59) | MAPTMEN1KMT2ACASP3SENP7 | |
| SCHEMBL15921270 | 0.82 | MAPT (0.53) | MAPTMEN1KMT2ACASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003095417-A1 | PROCESS FOR THE MANUFACTURE OF 4-FLUORO-ANTHRANILIC ACID | MITENI S.P.A. (IT) | 2003-11-20 | — | — | WO | claimed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024043242-A1 | HEART FAILURE TREATMENT VIA CARDIOTONIC EFFECT BY TRPC3/6/7 CHANNEL ACTIVATION | 国立大学法人九州大学 | 2024-02-29 | — | — | WO | disclosed |
| EP-3953360-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN LA ROCHE (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | HOFFMANN-LA ROCHE INC. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3953360-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2003095417-A1 | PROCESS FOR THE MANUFACTURE OF 4-FLUORO-ANTHRANILIC ACID | MITENI S.P.A. (IT) | 2003-11-20 | — | — | WO | disclosed |
| US-6451800-B1 | Phenylpiperazine derivatives as integrin αvβ3 antagonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6420558-B1 | COMPOUNDS WITH AMIDINE GROUPS ANTAGONISTIC ACTIVITY, CELL ADHESION INHIBITORY ACTIVITY, HUMAN PLATELET AGGREGATION INHIBITORY ACTIVITY, AND THERAPEUTIC AGENTS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1074543-A1 | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN ALPHA V BETA 3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2001-02-07 | — | — | EP | disclosed |
| EP-1057818-A1 | PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN ALPHAvBETA3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | MAPT 529/4885MEN1 3731/4885KMT2A 1583/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | MAPT 529/4885MEN1 3731/4885KMT2A 1583/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | MAPT 4555/4885MEN1 4497/4885KMT2A 1231/4885 |
| US-20220135591-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | MGLL, LIPC, PNLIP | MAPT 4343/4885MEN1 577/4885KMT2A 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.